课题基金 / 基金详情

Study on cellular signal transduction of Neurofibromatosis Type 2 tumor suppressor gene product (Merlin)

Study on cellular signal transduction of Neurofibromatosis Type 2 tumor suppressor gene product (Merlin)
神经纤维瘤病2型抑癌基因产物(Merlin)的细胞信号转导研究
批准号:
12671369
负责人:
ARAKI Norie
金额:
$2.5万
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2000
资助国家:
日本
项目状态:
已结题
起止时间:
2000 至 2001

项目摘要

项目成果

ARAKI Norie的其他基金

相似基金

相关文献

中文摘要
翻译
2型神经纤维瘤病(NF2)是一种常染色体显性遗传性疾病,与包括双侧前庭神经鞘瘤和脑膜瘤在内的良性颅内肿瘤的发生密切相关。NF2基因是最近被克隆的,其编码的蛋白(称为Merlin)与细胞骨架相关蛋白moesin-ezrin-Radisin(Mer)家族有惊人的相似性。为了阐明NF2蛋白(Merlin)的生物学功能,我们对Merlin的细胞定位和信号转导进行了分析。1)建立了突变体和野生型NF2的细胞表达系统,并用激光共聚焦扫描显微镜(CLSM)分析了它们的细胞定位。野生型Merlin表现出细胞质和膜下的定位,这是由其依赖于核输出信号(NES)的运输机制决定的。N-末端突变导致了Merlin的核积累。2)从牛BRA…中纯化了MERLIN的细胞结合蛋白通过对DNA-PK亚基Ku-抗原85和70内部氨基酸序列的分析,确定其为聚ADP-核糖聚合酶。Merlin的N-末端(19-339)区域是它们相互作用所必需的。免疫沉淀、Western blotting和CLMS研究证实了它们的细胞共定位。NF2突变损害了Merlin相关复合体的形成及其细胞信号传输。3)当NES受体CRM1的抑制剂LMB作用于VA13细胞和小鼠胚胎成纤维细胞(MEF)时,Merlin和PARP的亚细胞共定位主要分布在其核区。随着博莱霉素对细胞DNA的损伤,Merlin的这种核积聚增加。4)与野生型细胞相比,PARP基因缺陷的MEF即使在LMB和博莱霉素处理后也不能在其核区积聚Merlin,而PARP在这些细胞中的过表达与Merlin的细胞定位互补。这些结果表明,Merlin是一种胞质-核穿梭蛋白,由其依赖于NES的运输途径控制,与PARP相关。Merlin的肿瘤抑制作用可能通过PARP和DNA-PKs等细胞Merlin结合蛋白的相互作用与细胞DNA修复及相关信号联系。较少
英文摘要
The neurofibromatosis type 2 (NF2) is an autosomal dominantly inherited disorder, and strongly associated with development of benign intracranial tumors including bilateral vestibular schwannomas and meningiomas. NF2 gene was recently cloned, and the protein it encodes (termed as merlin) was found to be striking similarity to the moesin-ezrin-radixin (MER) family of cytoskeleton-associated proteins. To elucidate the biological function of NF2 protein (merlin), we analyzed the cellular localization and signal transduction of merlin. 1) Cellular expression systems of mutants or wild NF2 were established, and their cellular localization was analyzed by con focal lazer scanning microscopy (CLSM). The wild merlin showed cytoplasmic and submembranous localization that was found to be directed by its nuclear export signal (NES) dependent transport mechanism. The N-terminal mutation resulted in nuclear accumulation of merlin. 2) Cellular binding proteins of merlin were purified from bovine bra … More in extracts and identified as poly ADP-ribose polymerase, DNA-PK subunits Ku-antigen 85 and 70 by the analysis of their internal ammo-acid sequences. The N-terminal (19-339) region of merlin is essential for their interaction. The immuno-precipitation, western blotting, and CLMS study confirmed their cellular co-localization. NF2 mutations impair the merlin-related complex formation and their cellular signal transport. 3) Subcellular co-localizations of merlin and PARP, overexpressed in VA13 cells and mouse embryonic fibroblast (MEF), were observed mainly in their nuclear region when cells were treated with leptomycin B (LMB), an inhibitor of NES receptor Crm1. This nuclear accumulation of merlin increased with cellular DNA damages induced by bleomycin. 4) In marked contrast to wild type cells, PARP gene deficient MEF could not accumulate merlin in their nuclear region, even after the treatments of LMB and bleomycin, whereas the overexpression of PARP in those cells worked complementary to the cellular localization of merlin. These results suggest that merlin is a cytoplasmic-nuclear shuttling protein directed by its NES-dependent transport pathway being associated with PARP. The tumor suppressive function of merlin may be linked to cellular DNA-repair and related signals via the interaction of cellular merlin binding proteins such as PARP and DNA-PKs. Less
期刊论文(35)
专著(0)
科研奖励(0)
会议论文
Araki, N., et al.: "Proteomic analysis of tumor suppressor related proteins in central nervous system"J. Chromatogr. B. (in press). (2002)
Araki, N., et al.:“中枢神经系统肿瘤抑制相关蛋白的蛋白质组学分析”J.
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Araki,N., et.al.: "Proteomic analysis of tumor suppressor related proteins in brain."Protein Science. 9,(1). 162 (2000)
Araki,N., et.al.:“大脑中肿瘤抑制相关蛋白的蛋白质组学分析。”蛋白质科学。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Araki,N., et.al.: "New Development in Glycomedicine, Study of autoantibody against advanced glycation endproducts of the Maillard reaction."Elsevier Science B.V(in press). (2001)
Araki,N., et.al.:“糖医学的新发展,针对美拉德反应晚期糖基化终产物的自身抗体的研究。”Elsevier Science B.V(出版中)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
共 25 条
    Analysis of molecular network on maintenance and differentiation of glioma stem cells
    • 批准号:
      25640068
    • 项目类别:
      Grant-in-Aid for Challenging Exploratory Research
    • 资助金额:
      $2.58万
    • 财政年份:
      2013
    • 负责人:
      ARAKI Norie
    • 依托单位:
    System development for microquantitative molecular analyses ofglioma stem cells
    • 批准号:
      23659693
    • 项目类别:
      Grant-in-Aid for Challenging Exploratory Research
    • 资助金额:
      $2.33万
    • 财政年份:
      2011
    • 负责人:
      ARAKI Norie
    • 依托单位:
    Study of the molecular mechanism of neural tumor formation mediatedby NF1 gene deficiency
    • 批准号:
      22390281
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $12.23万
    • 财政年份:
      2010
    • 负责人:
      ARAKI Norie
    • 依托单位:
    Analysis of cellular signal transduction via Neurofibromatosis tumor suppressor gene products and development of their clinical targets
    • 批准号:
      19390382
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $11.9万
    • 财政年份:
      2007
    • 负责人:
      ARAKI Norie
    • 依托单位:
    国内基金
    海外基金
    NF2在Hippo信号通路稳态维持和机械力感知中的机制及功能研究
    • 批准号:
      32570833
    • 项目类别:
      面上项目
    • 资助金额:
      50.00万元
    • 批准年份:
      2025
    • 负责人:
      王瑜
    • 依托单位:
    LPS调控TFAM/NF2介导睾丸间质细胞铁死亡抑制雄激素合成的机制研究
    • 批准号:
      QN25H040004
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2025
    • 负责人:
      陈显武
    • 依托单位:
    基质硬度微环境中 UBXN1 通过调控 NF2 泛素 化激活 YAP/TAZ 通路促进 HCC 生长转移
    • 批准号:
      Y24H160144
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2024
    • 负责人:
      窦常伟
    • 依托单位:
    抑癌基因NF2调控恶性胸膜间皮瘤核苷酸代谢的分子机制及靶向干预
    • 批准号:
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2024
    • 负责人:
      许多
    • 依托单位: